Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24135551 | 0.87 | KCNJ1 (0.45) | KCNJ1MEN1KMT2AHRH3 | |
| SCHEMBL21850927 | 0.84 | KCNJ1 (0.46) | KCNJ1CXCR4HRH3 | |
| SCHEMBL21850925 | 0.81 | SIGMAR1 (0.38) | KCNJ1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL21851192 | 0.81 | KCNJ1 (0.40) | KCNJ1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL21851147 | 0.79 | KCNJ1 (0.41) | KCNJ1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL14606249 | 0.78 | SIGMAR1 (0.52) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850861 | 0.78 | KCNJ1 (0.52) | KCNJ1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL21850849 | 0.77 | SIGMAR1 (0.44) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850800 | 0.76 | KCNJ1 (0.51) | KCNJ1SIGMAR1CXCR4MEN1CHRM2 | |
| SCHEMBL14307263 | 0.74 | CXCR4 (0.53) | SIGMAR1CXCR4MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | KCNJ1 562/4885SIGMAR1 64/4885CXCR4 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.